Tri-specific killer engager cell therapy (Ingenium Therapeutics)

N/A

Report date: 2024/08/26 11:07:01

Base Information

Drug NameTri-specific killer engager cell therapy (Ingenium Therapeutics)
Drug Alias NameTriKE(TANK-E)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIngenium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesIngenium Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A